Alzheimer’s Disease Trials (AD)


The following are ongoing Alzheimer’s Disease clinical trials in Canada:


Study to Evaluate Efficacy of ALZ-801 in APOE4/4 Early AD Subjects (APOLLOE4)


Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer’s Disease (AD)


A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer’s Disease (AD)


A Second Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Gantenerumab Administration in Participants With Alzheimer’s Disease (AD)


A Study of LY3303560 in Participants With Early Symptomatic Alzheimer’s Disease (The PERISCOPE-ALZ Study


A Study of LY3002813 and LY3202626 in Participants With Early Symptomatic Alzheimer’s Disease (The TRAILBLAZER-ALZ Study)


A Study of Donanemab (LY3002813) in Participants With Early Alzheimer’s Disease (The TRAILBLAZER-ALZ 2 Study)


A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer’s Disease (TRAILBLAZER-EXT)


A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer’s Disease (INVOKE-2)


Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer’s Disease (BUENA)

A Study of JNJ-63733657 in Participants With Early Alzheimer’s Disease (The AUTONOMY Study)


Study of ANAVEX2-73 for Treatment of Early Alzheimer’s Disease)


A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205